ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

NCT06951646 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Immune Checkpoint Inhibitors (ICIs)

Interventions

DRUG: Ivonescimab
DRUG: Docetaxel
OTHER: Standard Treatment group

Sponsor

Second Xiangya Hospital of Central South University

Collaborators

[object Object]
[object Object]